News for Bio-Rad Laboratories, Inc. (BUWA.DE)

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc.

**media[550320]**

Shares of Bio-Rad Laboratories Inc (BIO) fell 9.91% in mid-day trading on Feb 14. The stock reached an intraday low of $275.99, down from its previous close o

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ETCompany ParticipantsEdward Chung - Vice President of...

Bio-Rad Laboratories Inc (BIO) is set to release its Q4 2024 earnings on Feb 13, 2025. The consensus estimate for Q4 2024 revenue is $679.30 million, and the ea

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc.

Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance LOUISVILLE, Col

Shares of Bio-Rad Laboratories Inc (BIO) surged 4.06% in mid-day trading on Jan 6. The stock reached an intraday high of $345.03, before settling at $344.17,

Summary Bio-Rad Laboratories Inc (BIO), a prominent player in life science research and clinical diagnostics, announced that its top executives will participate

Shares of Bio-Rad Laboratories Inc (BIO) fell 3.49% in mid-day trading on Dec 5. The stock reached an intraday low of $326.40, before recovering slightly to $

We came across a bullish thesis on Bio-Rad Laboratories, Inc. (BIO) on Substack by Stock Analysis Compilation. In this article, we will summarize the bulls’ thesis on BIO.

US small- and mid-cap equities, as measured by the Russell 2500 Index, rose in the third quarter of 2024.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company'

Shares of Bio-Rad Laboratories Inc (BIO) fell 8.54% in mid-day trading on Nov 16. The stock reached an intraday low of $319.25, before recovering slightly to

The U.S. Legionella Testing Market Size sector reached a market value of USD 103.6 million in 2022. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 9.2% from…

The U.S. Point of Care Diagnostics Market Size sector reached a market value of USD 9.45 billion in 2023. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 6.9%…

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cancer Cell Analysis...

All major U.S. indices posted gains in the third quarter with the economy demonstrating resilience and forecasters anticipating a soft landing.

Thyroid function testing industry is projected to witness a CAGR of 6.1% during the period 2024-2032. This growth can be attributed to advancements in...